Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 33, No. 4, 2003
Issue release date: July – August
Section title: Review Paper
Pathophysiol Haemost Thromb 2003/04;33:173–183

The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors

Nowak G.
Research Group ‘Pharmacological Haemostaseology’, Medical Faculty, Friedrich Schiller University Jena, Jena, Germany
email Corresponding Author

Prof. Dr. Götz Nowak

Friedrich Schiller University Jena, Medical Faculty

Research Group ‘Pharmacological Haemostaseology’

Drackendorfer Strasse 1, DE–07747 Jena (Germany)

Tel. +49 3641 932 57 00, Fax +49 3641 932 57 02, E-Mail goetz.nowak@med.uni-jena.de

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


The ecarin clotting time (ECT) is a meizothrombin generation test that allows for precise quantification of direct thrombin inhibitors. The ECT has demonstrated its usefulness for more than 10 years in biochemical-pharmacological investigations as well as in clinical research and in the clinical routine. It has proved valuable especially as a drug-monitoring method in r-hirudin therapy. This test has been adjusted to clinical requirements by numerous modifications. Following the description of the biochemical background and the measuring principle of the ECT, this article gives a short survey of several modifications of the ECT for both preclinical and clinical use, e.g., for biochemical investigations, as a point-of-care method and for cardiac surgery. Advantages and disadvantages of these methods are discussed.

© 2004 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Review Paper

Received: July 26, 2004
Accepted: September 14, 2004
Published online: December 02, 2004
Issue release date: July – August

Number of Print Pages: 11
Number of Figures: 11
Number of Tables: 0

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: http://www.karger.com/PHT

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.